# VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

> **NCT06447090** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Relapse Acute Myeloid Leukemia

## Interventions

- **DRUG:** Mitoxantrone hydrochloride liposome

## Key facts

- **NCT ID:** NCT06447090
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06447090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06447090, "VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06447090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*